Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press42210.17650/2222-1468-2019-9-3-49-60REVIEWОБЗОРНАЯ СТАТЬЯ18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in squamous cell carcinoma of the head and neck (literature review)Позитронная эмиссионная томография с 18F-фтордезоксиглюкозой, совмещенная с компьютерной томографией, при плоскоклеточном раке головы и шеи (обзор литературы)https://orcid.org/0000-0002-8483-0081RyzhovaО. D.РыжоваО. Д.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Ольга Дмитриевна Рыжова

115478 Москва, Каширское шоссе, 24olgaryzhova@mail.ruhttps://orcid.org/0000-0003-3930-5998DolgushinМ. B.ДолгушинМ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-7460-3267MikhaylovA. I.МихайловА. И.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-8404-0311DronovaЕ. L.ДроноваЕ. Л.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0003-2969-0191NevzorovD. I.НевзоровД. И.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0003-1255-5700MudunovА. М.МудуновА. М.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0002-6835-5567AlievaS. B.АлиеваС. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России311020199349603110201931102019Copyright ©; 2019, Ryzhova О.D., Dolgushin М.B., Mikhaylov A.I., Dronova Е.L., Nevzorov D.I., Mudunov А.М., Alieva S.B.Copyright ©; 2019, Рыжова О.Д., Долгушин М.Б., Михайлов А.И., Дронова Е.Л., Невзоров Д.И., Мудунов А.М., Алиева С.Б.2019Ryzhova О.D., Dolgushin М.B., Mikhaylov A.I., Dronova Е.L., Nevzorov D.I., Mudunov А.М., Alieva S.B.Рыжова О.Д., Долгушин М.Б., Михайлов А.И., Дронова Е.Л., Невзоров Д.И., Мудунов А.М., Алиева С.Б.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/422

Most of the malignant neoplasms of the head and neck are represented by squamous cell carcinoma. 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in squamous cell carcinoma of the head and neck is applied for primary staging, treatment planning, treatment response assessment evaluation and progression detection. The article presents a literature review on the use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in head and neck squamous cell carcinoma patients, and major trends of other radiopharmaceuticals usage in this nosology.

Бóльшая часть всех злокачественных новообразований головы и шеи представлена плоскоклеточным раком. Позитронная эмиссионная томография с 18F-фтордезоксиглюкозой, совмещенная с компьютерной томографией, при плоскоклеточном раке головы и шеи применяется для первичного определения стадии заболевания, планирования лечения и оценки его эффективности, выявления прогрессирования. Данный обзор научной литературы освещает вопросы применения позитронной эмиссионной томографии (с 18F-фтордезоксиглюкозой), совмещенной с компьютерной томографией, при плоскоклеточном раке головы шеи, а также основные тенденции использования других радиофармпрепаратов при этом заболевании.

squamous cell carcinomahead and neck tumorspositron emission tomography18F-fluorodeoxyglucoseплоскоклеточный ракопухоли головы и шеипозитронная эмиссионная томография18F-фтордезоксиглюкозаMalignant tumors in Russia in 2017 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, G.V. Petrova. Moscow: MNIOI im. P.A. Gertzena, 2018. 250 p. Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf. (In Russ.)Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2018. 250 с. Доступно по: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.PET/CT in head and neck cancer. Ed. by Wai Lup Wong. Springer International Publishing, 2018. DOI: 10.1007/978-3-319-61440-3.MR imaging of the body. Ed. by E.J. Rummeny, P. Reimer, W. Heindel. Stuttgart; New York: Thieme, 2009. 1856 p.Wong W.L., Sonoda L.I., Gharpurhy A. et al. 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers – an audit and review of published studies. Clin Oncol (R Coll Radiol) 2012;24(3):190–5. DOI: 10.1016/j.clon.2011.11.001.Wong W.L., Sonoda L.I., Gharpurhy A. et al. 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers – an audit and review of published studies. Clin Oncol (R Coll Radiol) 2012;24(3):190–5. DOI: 10.1016/j.clon.2011.11.001.Alieva S.B., Alymov Yu.V., Kropotov M.A. et al. Clinical recommendations for the diagnosis and treatment of squamous cell carcinoma of the head and neck. Moscow, 2014. Available at: http://www.oncology.ru/association/clinical-guidelines/2014/36.pdf. (In Russ.)Алиева С.Б., Алымов Ю.В., Кропотов М.А. и др. Клинические рекомендации по диагностике и лечению плоскоклеточного рака головы и шеи. М., 2014. Доступно по: http://www.oncology.ru/association/clinical-guidelines/2014/36.pdf.Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Practical recommendations for the treatment of malignant tumors of the head and neck. Zlokachestvennye opukholi = Malignant Tumors 2018; 8(3 Suppl):71–82. Available at: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-05.pdf. (In Russ.). DOI: 10.18 027/2224-5057-2018-8-3s2-71-82.Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В. и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи. Злокачественные опухоли 2018; 8(3, прил.):71–82. Доступно по: https://rosoncoweb.ru/standarts/RUSSCO/2018/2018-05.pdf. DOI: 10.18 027/2224-5057-2018-8-3s2-71-82.National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN guidelines). Version 2.2019 for Head and Neck Cancers. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.Zhu L., Wang N. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis. Surg Oncol 2013;22(3):190–4. DOI: 10.1016/j.suronc.2013.06.002.Zhu L., Wang N. 18 F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis. Surg Oncol 2013;22(3):190–4. DOI: 10.1016/j.suronc.2013.06.002.Schwarz E., Hürlimann S., Soyka J.D. et al. FDG-positive Warthin’s tumors in cervical lymph nodes mimicking metastases in tongue cancer staging with PET/CT. Otolaryngol Head Neck Surg 2009;140(1):134–5. DOI: 10.1016/j.otohns.2008.09.019.Noij D.P., Pouwels P.J.W., Ljumanovic R. et al. Predictive value of diffusion-weighted imaging without and with including contrast-enhanced magnetic resonance imaging in image analysis of head and neck squamous cell carcinoma. Eur J Radiol 2015;84(1):108–16. DOI: 10.1016/j.ejrad.2014.10.015.Kyzas P.A., Evangelou E., Denaxa-Kyza D., Ioannidis J.P. 18 F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100(10):712–20. DOI: 10.1093/jnci/djn125.Kyzas P.A., Evangelou E., Denaxa-Kyza D., Ioannidis J.P. 18 F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100(10):712–20. DOI: 10.1093/jnci/djn125.Sun R., Tang X., Yang Y., Zhang C. (18)FDG-PET/CT for the detection of regional nodal metastasis in patients with head and neck cancer: a meta-analysis. Oral Oncol 2015;51(4):314–20. DOI: 10.1016/j.oraloncology.2015.01.004.Mak D., Corry J., Lau E. et al. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging 2011;55(5):487–99.Schöder H., Carlson D.L., Kraus D.H. et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47(5):755–62.Rodrigo J.P., Grilli G., Shah J.P. et al. Selective neck dissection in surgically treated head and neck squamous cell carcinoma patients with a clinically positive neck: systematic review. Eur J Surg Oncol 2018;44(4):395–403. DOI: 10.1016/j.ejso.2018.01.003.Haerle S.K., Strobel K., Ahmad N. et al. Contrast-enhanced 18 F-FDG-PET/CT for the assessment of necrotic lymph node metastases. Head Neck 2011;33(3):324–9. DOI: 10.1002/hed.21447.Haerle S.K., Strobel K., Ahmad N. et al. Contrast-enhanced 18 F-FDG-PET/CT for the assessment of necrotic lymph node metastases. Head Neck 2011;33(3):324–9. DOI: 10.1002/hed.21447.Saindane A.M. Pitfalls in the staging of cervical lymph node metastasis. Neuroimaging Clin N Am 2013;23(1):147–66. DOI: 10.1016/j.nic.2012.08.011.Xu G.Z., Zhu X.D., Li M.Y. Accuracy of whole-body PET and PET-CT in initial M staging of head and neck cancer: a meta-analysis. Head Neck 2011;33(1):87–94. DOI: 10.1002/hed.21400.Griffioen G.H., Louie A.V., de Bree R. et al. Second primary lung cancers following a diagnosis of primary head and neck cancer. Lung Cancer 2015;88(1):94–9. DOI: 10.1016/j.lungcan.2015.01.011.Jain K.S., Sikora A.G., Baxi S.S., Morris L.G. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer 2013;119(10):1832–7. DOI: 10.1002/cncr.27988.Rose B.S., Jeong J.H., Nath S.K. et al. Population-based study of competing mortality in head and neck cancer. J Clin Oncol 2011;29(26):3503–9. DOI: 10.1200/JCO.2011.35.7301.Strobel K., Haerle S.K., Stoeckli S.J. Head and neck squamous cell carcinoma (HNSCC) – detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2009;36(6): 919–27. DOI: 10.1007/s00259-009-1064-6.Higgins K.A., Hoang J.K., Roach M.C. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys 2012;82(2):548–53. DOI: 10.1016/j.ijrobp.2010.11.050.Xie P., Li M., Zhao H. 18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. J Cancer Res Clin Oncol 2011;137(7):1085–93. DOI: 10.1007/s00432-010-0972.Schinagl D.A., Span P.N., Oyen W.J., Kaanders J.H. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 2011;38(8):1449–58. DOI: 10.1007/s00259-011-1789.Rohde M., Nielsen A.L., Johansen J. Up-front PET/CT changes treatment intent in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2018;45(4):613–21. DOI: 10.1007/s00259-017-3873-3.Weber W.A. Assessing tumor response to therapy. J Nucl Med 2009;50 Suppl 1: 1S–10S. DOI: 10.2967/jnumed.108.057174.Arens A.I., Troost E.G., Schinagl D. et al. FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma. Q J Nucl Med Mol Imaging 2011;55(5):521–8.Wong K.W., Kwong D.L.W., Khong P.L. et al. Delineation of biological tumor volume from positron emission tomography images in nasopharyngeal carcinoma. J Biomed Sci Engineering 2014;07(11):857–65. DOI: 10.4236/jbise.2014.711085.Henriques de Figueiredo B.H., Zacharatou C., Galland-Girodet S. et al. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers. Strahlentherapie Onkol 2015;191(3):217–24. DOI: 10.1007/s00066-014-0752-8.Okamoto S., Shiga T., Yasuda K. et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013;54(2):201–7. DOI: 10.2967/jnumed.112.109330.Ware R.E., Matthews J.P., Hicks R.J. et al. Usefulness of fluorine‐18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 2004;26(12):1008–17. DOI: 10.1002/hed.20097.Porceddu S.V., Pryor D.I., Burmeister E. et al. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck 2011;33(12):1675–82. DOI: 10.1002/hed.21655.Yao M., Smith R.B., Hoffman H.T. et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer – a long-term outcome report. Int J Radiat Oncol Biol Phys 2009;74(1):9–14. DOI: 10.1016/j.ijrobp.2008.07.019.Leung A.S., Rath T.J., Hughes M.A. et al. Optimal timing of first posttreatment FDG PET/CT in head and neck squamous cell carcinoma. Head Neck 2016;38 Suppl 1: E853–8. DOI: 10.1002/hed.24112.Lefebvre J.L., Ang K.K. Larynx preservation clinical trial design: key issues and recommendations – a consensus panel summary. Int J Radiat Oncol Biol Phys 2009;73(5):1293–303. DOI: 10.1016/j.ijrobp.2008.10.047.Castaldi P., Rufini V., Bussu F. et al. Can “early” and “late” 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy? Radiother Oncol 2012;103(1):63–8. DOI: 10.1016/j.radonc.2012.03.001.Farrag A., Ceulemans G., Voordeckers M. et al. Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 2010;31(6):495–501. DOI: 10.1097/MNM.0b013e3283334e2b.Hentschel M., Appold S., Schreiber A. et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 2011;38(7):1203–11. DOI: 10.1007/s00259-011-1759-3.Marcus C., Ciarallo A., Tahari A.K. et al. Head and neck PET/CT: therapy response interpretation criteria (Hopkins criteria) – interreader reliability, accuracy, and survival outcomes. J Nucl Med 2014;55(9):1411–6. DOI: 10.2967/jnumed.113.136796.Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32(27):3059–68. DOI: 10.1200/JCO.2013.54.8800.Sjövall J., Bitzén U., Kjellén E. et al. Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2016;43(4):609–16. DOI: 10.1007/s00259-015-3194-3.Aiken A.H., Farley A., Baugnon K.L. et al. Implementation of a novel surveillance template for head and neck cancer: Neck Imaging Reporting and Data System (NI-RADS). J Am Coll Radiol 2016;13(6):743–6. DOI: 10.1016/j.jacr.2015.09.032.Castaldi P., Leccisotti L., Bussu F. et al. Role of (18)F-FDG PET-CT in head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013;33(1):1–8.Mirabile A., Miceli R., Calderone R.G. et al. Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2019;41(6):1895–902. DOI: 10.1002/hed.25636.Isles M.G., McConkey C., Mehanna H.M. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33(3):210–22. DOI: 10.1111/j.1749-4486.2008.01688.Abgral R., Querellou S., Potard G. et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med 2009;50(1):24–9. DOI: 10.2967/jnumed.108.055806.Liu T., Xu W., Yan W.L. et al. FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review. Radiother Oncol 2007;85(3):327–35. DOI: 10.1016/j.radonc.2007.11.002.Krabbe C.A., Pruim J., Dijkstra P.U. et al. 18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study. J Nucl Med 2009;50(12):1940–7. DOI: 10.2967/jnumed.109.065300.Gupta T., Master Z., Kannan S. et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011;38(11):2083–95. DOI: 10.1007/s00259-011-1893.Chen Y.J., Rath T., Mohan S. PET-computed tomography in head and neck cancer: current evidence and future directions. Magn Reson Imaging Clin N Am 2018;26(1):37–49. DOI: 10.1016/j.mric.2017.08.003.Benedetto R., Massicano A.V.F., Crenshaw B.K. et al. 89 Zr-DFO-cetuximab as a molecular imaging agent to identify cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biother Radiopharm 2019;34(5):288–96. DOI: 10.1089/cbr.2018.2616.Benedetto R., Massicano A.V.F., Crenshaw B.K. et al. 89 Zr-DFO-cetuximab as a molecular imaging agent to identify cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biother Radiopharm 2019;34(5):288–96. DOI: 10.1089/cbr.2018.2616.Even A.J., Hamming-Vrieze O., van Elmpt W. et al. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. Oncotarget 2017;8(3):3870–80. DOI: 10.18632/oncotarget.13910.